| Document and Entity Information | Nov. 12, 2020 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Document Period End Date | Nov. 12, 2020 |
| Entity Registrant Name | TRAVERE THERAPEUTICS, INC. |
| Entity Incorporation, State or Country Code | DE |
| Entity File Number | 001-36257 |
| Entity Tax Identification Number | 27-4842691 |
| Entity Address, Address Line One | 3611 Valley Centre Drive |
| Entity Address, Address Line Two | Suite 300 |
| Entity Address, City or Town | San Diego |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92130 |
| City Area Code | 888 |
| Local Phone Number | 969-7879 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share |
| Trading Symbol | RTRX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Entity Information, Former Legal or Registered Name | Retrophin, Inc. |
| Entity Central Index Key | 0001438533 |
| Amendment Flag | true |
| Amendment Description | This Amendment No. 1 to Current Report on Form 8-K (“Amendment No. 1”) is being filed to amend the Current Report on Form 8-K filed by Travere Therapeutics, Inc. (f/k/a “Retrophin, Inc.”) (the “Company”) with the Securities and Exchange Commission on November 12, 2020 (the “Original 8-K”). Subsequent to filing the Original 8-K, the Company determined that the date of completion of the closing of the transaction described therein should have been reported as November 12, 2020, rather than November 10, 2020. Likewise, the Date of Report on the first page of the Original 8-K should have been reflected as November 12, 2020, rather than November 10, 2020. This Amendment No. 1 amends the Original 8-K to reflect the correct date of the completion of the closing of the transaction described in the Original 8-K and the correct Date of Report. Other than as described above in this Explanatory Note and other than changes to reflect the Company’s name change effected on November 13, 2020, no other changes have been made to the Original 8-K. In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, the complete text of Item 8.01 of the Original 8-K, as amended hereby, is set forth below. |
